Fundraising Fox

ILiAD Biotechnologies

Weston, US · Founded 2026 · Delaware corporation · 1 known investors

ILiAD Biotechnologies is a clinical-stage biotechnology company developing vaccines and treatments for disease caused by Bordetella pertussis, with a lead candidate, BPZE1, a next-generation pertussis vaccine that has completed four Phase 2 clinical trials. It operates a wholly-owned subsidiary, BioLyo Technologies, a contract development and manufacturing organization for live bacterial products based in Ghent, Belgium.

BiotechHealthtech

Founders & leadership

ILiAD Biotechnologies was founded in 2026 by Keith Rubin.

KRKeith Rubin
Keith RubinFounder
WS
William SteinkraussExecutive
KS
KEN SOLOVAYNamed on SEC filing

Board

EE
Eric EdidinBoard director
AN
Avi NaiderBoard director
MB
Mario BarroBoard director

Investors · 1

RA CapitalBoston

Reported raises · per SEC filings

Form D private placements

$170.3M disclosed across 10 of 12 rounds · 2015–2026

▶$115.5MraisedFeb 2026 · 36 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • William SteinkraussExecutive Officer
  • Avi NaiderDirector
  • Mario BarroDirector
  • Eric EdidinDirector
  • Keith RubinExecutive Officer, Director
Offering amount
$115.5M
Amount sold
$115.5M
Sales commissions
$1.1M
Proceeds to insiders
$208.2K
Placement agents
Walter C. Greenblatt & Associates
First sale
Feb 2026
Incorporated
Corporation, Delaware, 2026
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3MraisedOct 2022 · 43 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Eric EdidinDirector
  • Corey HorowitzDirector
  • Bin YanDirector
  • Ken SolovayExecutive Officer
  • David JohnstonExecutive Officer
  • Avi NaiderDirector
  • Keith RubinExecutive Officer, Director
  • Ariel Pablos-MendezDirector
  • Cuong DoDirector
Offering amount
$3M
Amount sold
$3M
Sales commissions
$28.3K
Placement agents
Walter C. Greenblatt & Associates
First sale
Oct 2022
Incorporated
Limited Liability Company, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$42.8MraisedSep 2022 · 42 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Ken SolovayExecutive Officer
  • David JohnstonExecutive Officer
  • Ariel Pablos-MendezDirector
  • Keith RubinExecutive Officer, Director
  • Eric EdidinDirector
  • Corey HorowitzDirector
  • Bin YanDirector
  • Cuong DoDirector
  • Avi NaiderDirector
Offering amount
$42.8M
Amount sold
$42.8M
Sales commissions
$2.4M
Proceeds to insiders
$1.5M
Placement agents
Walter C. Greenblatt & Associates, Cabot Lodge Securities, LLC, Guggenheim Securities, LLC
First sale
Aug 2022
Incorporated
Limited Liability Company, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$23.5MofferedMar 2021 · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • KEITH RUBINExecutive Officer, Director
  • KEN SOLOVAYExecutive Officer, Director
  • CUONG DODirector
  • BIN YANDirector
  • COREY HOROWITZDirector
  • ARIEL PABLOS-MENDEZDirector
Offering amount
$23.5M
Sales commissions
$630K
Proceeds to insiders
$1.4M
Placement agents
WALTER GREENBLATT & ASSOCIATES
Incorporated
Limited Liability Company, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4.3MraisedMar 2020 · 36 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • ARIEL PABLOS-MENDEZDirector
  • KEN SOLOVAYExecutive Officer
  • CUONG DODirector
  • KEITH RUBINExecutive Officer, Director
  • COREY HOROWITZDirector
  • BIN YANDirector
Offering amount
$4.8M
Amount sold
$4.3M
Sales commissions
$368K
Proceeds to insiders
$660K
Placement agents
WALTER GREENBLATT & ASSOCIATES
First sale
Nov 2019
Incorporated
Limited Liability Company, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$20MofferedMar 2019 · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • KEITH RUBINExecutive Officer, Director
  • KEN SOLOVAYExecutive Officer
  • BIN YANDirector
  • CUONG DODirector
Offering amount
$20M
Sales commissions
$1.3M
Proceeds to insiders
$1.8M
Placement agents
WALTER GREENBLATT & ASSOCIATES
Incorporated
Limited Liability Company, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$550KraisedAug 2018 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • CUONG DODirector
  • KEN SOLOVAYExecutive Officer
  • BIN YANDirector
  • KEITH RUBINExecutive Officer, Director
Offering amount
$5M
Amount sold
$550K
Sales commissions
$400K
Proceeds to insiders
$500K
Placement agents
WALTER GREENBLATT & ASSOCIATES
First sale
Jul 2018
Incorporated
Limited Liability Company, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$675.2KraisedFeb 2018 · 11 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • KEN SOLOVAYExecutive Officer
  • KEITH RUBINExecutive Officer
Offering amount
$5M
Amount sold
$675.2K
Sales commissions
$33.8K
Proceeds to insiders
$100K
Placement agents
WALTER GREENBLATT & ASSOCIATES
First sale
Jan 2018
Incorporated
Limited Liability Company, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap
Doximity8 shared keywordsDoximity is the largest verified network of healthcare professionals in the U.S., connecting physicians, PAs, NPs, pharmacists, and medical students across specialties and care settings. The platform provides mobile-first tools for clinical communication, collaboration, and workflow optimization.

Companies competing with ILiAD Biotechnologies for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

ILiAD Biotechnologies of Weston raises $115M to advance whooping cough vaccine - Refresh Miamirefreshmiami.com · Feb 2026ILiAD Biotechnologies Raises $115M in Series B Fundingfinsmes.com · Feb 2026ILiAD Biotechnologies Announces $115M Oversubscribed Series B Financing to Advance BPZE1 Pertussis Vaccine - BioSpacebiospace.com · Feb 2026ILiAD Biotechnologies of Weston closes $42.8M Series D - Refresh Miamirefreshmiami.com · Sep 2022

Frequently asked questions

What does ILiAD Biotechnologies do?
ILiAD Biotechnologies is a clinical-stage biotechnology company developing vaccines and treatments for disease caused by Bordetella pertussis, with a lead candidate, BPZE1, a next-generation pertussis vaccine that has completed four Phase 2 clinical trials. It operates a wholly-owned subsidiary, BioLyo Technologies, a contract development and manufacturing organization for live bacterial products based in Ghent, Belgium.
Who founded ILiAD Biotechnologies?
ILiAD Biotechnologies was founded by Keith Rubin in 2026.
Who are ILiAD Biotechnologies's investors?
ILiAD Biotechnologies's investors include RA Capital.
How much funding has ILiAD Biotechnologies raised?
ILiAD Biotechnologies has disclosed $170.3M raised across 10 of its 12 known rounds.
Where is ILiAD Biotechnologies headquartered?
ILiAD Biotechnologies is headquartered in Weston, US.